H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough” to Olema Oncology’s (OLMA) OPERA-02 trial, which is evaluating palazestrant plus ribociclib. Differences in combo agents could favor OPERA-02, argues the analyst, who keeps a Buy rating on Olema shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OLMA:
